goodandevil
Member
- Joined
- May 27, 2015
- Messages
- 978
See warnings: LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION, USP 2% (VISCOUS)
Usual adult dose is one tablespoon. don't eat until the lidocaine has worn off.
I:" I have burning eyes, burning throat and sinus cavity, etc. Definitely related to gut."
Ray:"Years ago I swallowed a sip of 2% lidocaine gel, and within a few minutes felt something changing in my intestine, and from then on, without any more lidocaine, some of my bowel symptoms were gone."
I: "Excellent! I just happen to have some on hand. Epigenetic?"
Ray: "I think that must be it, for the improvement to be so stable."
Usual adult dose is one tablespoon. don't eat until the lidocaine has worn off.
I:" I have burning eyes, burning throat and sinus cavity, etc. Definitely related to gut."
Ray:"Years ago I swallowed a sip of 2% lidocaine gel, and within a few minutes felt something changing in my intestine, and from then on, without any more lidocaine, some of my bowel symptoms were gone."
I: "Excellent! I just happen to have some on hand. Epigenetic?"
Ray: "I think that must be it, for the improvement to be so stable."
Br J Anaesth. 2014 Jul;113 Suppl 1:i32-8.
Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid
in breast cancer cells in vitro.
Lirk P(1), Hollmann MW(2), Fleischer M(3), Weber NC(2), Fiegl H(4).
(1)Department of Anaesthesiology, Academic Medical Center, University of
Amsterdam, Meibergdreef 9, Amsterdam 1105AZ, The Netherlands [email protected]
[email protected]. (2)Department of Anaesthesiology, Academic Medical
Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105AZ, The
Netherlands. (3)Department of Gynaecology and Obstetrics, Innsbruck Medical
University, Anichstr. 35, Innsbruck 6020, Austria. (4)Department of Gynaecology
and Obstetrics, Innsbruck Medical University, Anichstr. 35, Innsbruck 6020,
Austria [email protected] [email protected].
BACKGROUND: Lidocaine demethylates deoxyribonucleic acid (DNA) in breast cancer
cells. This modification of epigenetic information may be of therapeutic
relevance in the perioperative period, because a decrease in methylation can
reactivate tumour suppressor genes and inhibit tumour growth. The objectives of
this study were to determine the effect of two amide local anaesthetics,
ropivacaine and bupivacaine, on methylation in two breast cancer cell lines and
to detect whether the combination of lidocaine with the chemotherapy agent
5-aza-2'-deoxycytidine (DAC) would result in additive demethylating effects.
METHODS: Breast cancer cell lines BT-20 [oestrogen receptor (ER)-negative] and
MCF-7 (ER-positive) were incubated with lidocaine, bupivacaine, and ropivacaine
to assess demethylating properties. Then, we tested varying concentrations of
lidocaine and DAC to assess whether their demethylating effects were additive.
Cell numbers and global methylation status were analysed.
RESULTS: Lidocaine decreased methylation in BT-20 and MCF-7 cells, ropivacaine
decreased methylation in BT-20 cells, and bupivacaine had no demethylating
effect. When combined, lidocaine and DAC had additive demethylating effects.
CONCLUSIONS: At clinically relevant doses, lidocaine and ropivacaine exert
demethylating effects on specific breast cancer cell lines, but bupivacaine does
not. The demethylating effects of lidocaine and DAC are indeed additive.
© The Author [2014]. Published by Oxford University Press on behalf of the
British Journal of Anaesthesia. All rights reserved. For Permissions, please
email: [email protected].
Last edited by a moderator: